TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02713555

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Roux-en-Y Gastric Bypass
Description: Roux-en-Y Gastric Bypass surgery entails the formation of a small gastric pouch and the division of the small intestine 60 cm from the duodenum. Formation of a gastrojejunal anastomosis with the distal segment and the formation of a jejuno-jejunal anastomosis 150 cm from the gastrojejunal anastomosis with the biliary segment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastric Sleeve
Description: Gastric Sleeve entails a vertical division of the stomach with a stapler.
Study: NCT02559830

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: transduced CD34+ hematopoietic stem cell
Description: Autologous hematopoietic stem cells (HSCs) collected from the mobilized peripheral blood and transduced ex vivo with a Lentiviral vector encoding the human ARSA(for MLD)/ABCD1(for ALD) cDNA（complementary DNA）. Dose: ≥ 2x10\^6 transduced CD34+ cells/Kg (maximum 20x10\^6) at bedside for infusion.
Study: NCT04102592

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Permethrin-treated Lesu (baby wrap)
Description: 0.5% permethrin application

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Untreated Lesu (baby wrap)
Description: Matching untreated lesu
Study: NCT04110093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib and PD-1 inhibitor
Description: All Colorectal cancer patients received regorafenib (80mg qd d1-d21,q4w) and PD-1 inhibitor. The patients could receive one type of PD-1 inhibitors according to oneself circumstance consideration including nivolumab (3mg/kg, ivgtt, q2w), Carelizumab (200mg, ivgtt, q3w), Sintilimab (200mg, ivgtt, q3w), Toripalimab(240mg ivgtt, q3w).
Study: NCT05146531

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: McCoy laryngoscope
Description: Patients scheduled for general anesthesia were intubated with McCoy laryngoscope.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-MAC D-blade video laryngoscope
Description: Patients scheduled for general anesthesia were intubated with C-MAC D-blade video laryngoscope.
Study: NCT03110653

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0.9%
Description: NaCl 0.9% will be administered postoperatively, while being decreased by 30% every 15 mins.
Study: NCT01022515

Intervention type: OTHER
Intervention: plasma EM66 & CgA levels assessment
Description: After inclusion checking to eliminate the presence of pheochromocytoma / paraganglioma, a blood sample will be drawn to assess plasma EM66 and CgA levels.

Intervention type: OTHER
Intervention: usual follow up with regular EM66 & Cga levels assessment
Description: Patients with pheochromocytoma / paraganglioma will be followed-up as the international standards recommend.~Regularly, blood samples will be drawn for the usual assessment of CgA levels and also EM66 (research purpose) levels.
Study: NCT00611468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: All subjects receive treatment with intravenous topotecan and oral erlotinib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: All subjects receive treatment with intravenous topotecan and oral erlotinib.
Study: NCT02439424

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reactive ATP
Description: Reactive ATP turned to on
Study: NCT02293265

Intervention type: DRUG
Group type: OTHER
Intervention: Short Acting Beta Agonist (SABA)
Description: Participants requiring a spirometry measurement will be administered a SABA in a metered dose inhaler (MDI) during the reversibility assessments
Study: NCT00803348

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bolus of 0.2% ropivicaine 20 mls followed by 0.2% ropivicaine at an infusion rate of 5mls/hr until 0600 on postoperative day 2
Description: Initial bolus of 0.2% ropivicaine 20 mls into the femoral catheter followed by 0.2% ropivicaine at an infusion rate of 5mls/hr with patient controlled boluses of 5ml available every 30 mins, until 0600 on the morning of postoperative day 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bolus of 0.2% ropivicaine 20 mls followed by 0.1% ropivicaine at an infusion rate of 10mls/hr until 0600 on post-operative day 2
Description: Initial bolus of 0.2% ropivicaine 20 mls into the femoral catheter followed by 0.1% ropivicaine at an infusion rate of 10mls/hr with patient controlled boluses of 10mls available every 30 mins, until 0600 on the morning of postoperative day 2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline control
Description: Bolus of 0.375% ropivicaine 30 mls followed by saline infusion until 0600 on postoperative day 2
Study: NCT04149223

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evidence-based standardized Cirrhosis order set
Description: Standardized order sets for guidance in ascites, varices, hepatic encephalopathy, infections, and medication reconciliation (optimizing HE medication, medication prophylaxis, withdrawal of non-indicated proton pump inhibitors).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Evidence-based standardized Cirrhosis order set
Description: Standardized order sets for guidance in ascites, varices, hepatic encephalopathy, infections, and medication reconciliation (optimizing HE medication, medication prophylaxis, withdrawal of non-indicated proton pump inhibitors).
Study: NCT04233658

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3x2 capsules / day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cynara Scolymus
Description: 3x2 capsules / day
Study: NCT04699812

Intervention type: DEVICE
Group type: OTHER
Intervention: ELECTROCARDIOGRAM (ECG) PATCH WEAR
Description: ALL PARTICIPANTS WILL WEAR AN ECG PATCH ON THEIR UPPER LEFT CHEST THROUGHOUT THE STUDY PARTICIPATION

Intervention type: DEVICE
Group type: OTHER
Intervention: ELECTROCARDIOGRAM (ECG) PATCH WEAR
Description: ALL PARTICIPANTS WILL WEAR AN ECG PATCH ON THEIR UPPER LEFT CHEST THROUGHOUT THE STUDY PARTICIPATION

Intervention type: DEVICE
Group type: OTHER
Intervention: ELECTROCARDIOGRAM (ECG) PATCH WEAR
Description: ALL PARTICIPANTS WILL WEAR AN ECG PATCH ON THEIR UPPER LEFT CHEST THROUGHOUT THE STUDY PARTICIPATION

Intervention type: DEVICE
Group type: OTHER
Intervention: ELECTROCARDIOGRAM (ECG) PATCH WEAR
Description: ALL PARTICIPANTS WILL WEAR AN ECG PATCH ON THEIR UPPER LEFT CHEST THROUGHOUT THE STUDY PARTICIPATION
Study: NCT04207918

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 44.94Gy and 37.8Gy in 21 fractions to PGTV and PTV for neoadjuvant treatment. 59.92Gy and 50.4Gy in 28 fractions to PGTV and PTV for definitive treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: 400mg, by intravenous infusion once a week in 4-6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: 40-60mg/m2/d，orally twice a day concurrently with radiotherapy.
Study: NCT02154048

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02948907

Intervention type: OTHER
Group type: OTHER
Intervention: Procedure/Bronchoscopy
Description: Patients with enlarged hilar and/or mediastinal lymph nodes and indication for EBUS-TBNA undergo diagnostic bronchoscopy. For characterisation of the enlarged lymph nodes endobronchial ultrasound with elastography and Tissue Harmonic Imaging (THI) are used. Afterwards, EBUS-TBNA is performed. The results of elastography and THI are correlated with the cytological result obtained by EBUS-TBNA.
Study: NCT03171974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: dexamethasone will be injected intracapsular under US

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: US
Description: dexamethasone will be injected intracapsular under US
Study: NCT02308566

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimized Extracorporeal Circulation (MECC)
Description: This group of patients receives surgical aortic valve replacement using MECC.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Extracorporeal Circulation (CECC)
Description: This group of patients receives surgical aortic valve replacement using CECC.
Study: NCT02334813

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Continuous daily therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 4-day pulses every 3 weeks
Study: NCT02306928

Intervention type: OTHER
Intervention: Blood draw
Study: NCT04052984

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delayed umbilical clamping and immediate skin-to-skin contact after birth by caesarean section
Description: Mother: Placement of the insulating surgical arch was on the skin, between the abdomen and the thorax, electrocautery plate on the back, the gown superimposed, non-invasive blood pressure monitoring in legs and ear oximetry. The newborn was placed immediately on the mother's chest, passing it under the insulating arch and removing the mother's gown. Non-invasive monitoring was initiated with preductal pulse oximetry. The obstetrician cut the umbilical cord by not feeling the beats of the cord, or until 5 minutes. The newborn was reanimated without separating the baby from his mother. The temperature was taken with an infrared thermometer. Pulse oximetry was recorded. The newborn was colocated to the mother's breast as soon as possible, even if the mother was still in surgery. The mother's transfer to her room was with her baby skin to skin. The support staff was instructed not to separate the newborn until breast feeding occur for the first time or the mother required it.
Study: NCT00868075

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chest physiotherapy
Description: Twice daily for 8 weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chest Physiotherapy + Exercise Program
Description: Twice daily chest physiotherapy and Three times weekly exercise program (two sessions supervised)for 8 weeks
Study: NCT01671176

Intervention type: DEVICE
Group type: OTHER
Intervention: Wide diameter bone anchored implant
Description: 4.5 mm wide diameter bone anchored implant
Study: NCT01207921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Study: NCT02579525

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hemodynamical treatment TTP
Description: Based on capillary refilling time, peripheral temperature, mottling, diuresis, MAP safety limit monitoring

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hemodynamical treatment MCG
Description: Based on MAP, CVP, urine output monitoring
Study: NCT02672306

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCMSCs
Description: Biological: Human UCMSCs 20 million cells per subject (0.5×10\^6 UCMSCs per kg) intravenous injection Infusion number: 8 (Once every two weeks)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects with Alzheimer's Disease placebo comparator (normal saline) intravenous injection Infusion number: 8 (Once every two weeks)
Study: NCT04479306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Given PO
Study: NCT04148378

Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention for this study.
Study: NCT04160559

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: green tea
Description: The investigators require patients to regularly drink green tea during the trial period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: green tea
Description: The investigators require patients to regularly drink green tea during the trial period.
Study: NCT01858272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H5.020CMV.PDGF-b and limb compression bandage
Study: NCT02953977

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Diabetes Prevention Program
Description: An adapted version of the Diabetes Prevention Program will be delivered to intervention participants.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Prevention Program
Description: An adapted version of the Diabetes Prevention Program will be delivered to intervention participants.
Study: NCT00710866

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Influenza Vaccine Trivalent Types A and B (Split Virion)
Description: Arm 1 (experimental group) received two spaced injections of the 0.5 mL (full) dose while arm 2 (comparison group) received the currently recommended two spaced injections of 0.25mL (half) dose of trivalent inactivated split virion influenza vaccine (VAXIGRIP®) manufactured by Sanofi Pasteur, Lyon, France.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated Influenza Vaccine Trivalent Types A and B (Split Virion)
Description: Arm 1 (experimental group) received two spaced injections of the 0.5 mL (full) dose while arm 2 (comparison group) received the currently recommended two spaced injections of 0.25mL (half) dose of trivalent inactivated split virion influenza vaccine (VAXIGRIP®) manufactured by Sanofi Pasteur, Lyon, France.
Study: NCT00631566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mupirocin (Bactroban) 2%; hexachlorophene (pHisoHex) 3%
Description: BACTROBAN NASAL is a white to off-white ointment that contains 2.15% w/w mupirocin calcium (equivalent to 2.0% pure mupirocin free acid) in a soft white ointment base. The inactive ingredients are paraffin and a mixture of glycerin esters (SOFTISAN 649).~pHisoHex, brand of hexachlorophene detergent cleanser, is an antibacterial sudsing emulsion for topical administration.~Some randomized patients will receive mupirocin (Bactroban) nasal ointment plus hexachlorophene (pHisoHex) body washes for seven days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Some randomized patients will receive a placebo nasal ointment (white petroleum) and a placebo body soap with no antimicrobial activity for seven days.
Study: NCT01481142

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: (GMA) Adsorptive Apheresis
Description: Patients will be treated with once-weekly Adacolumn® apheresis over 5 consecutive weeks; treatment can be extended to up to 10 treatments administered once weekly over 10 weeks.
Study: NCT04021173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anfibatide
Description: 5 IU/60kg intravenous infusion follow by 0.002 IU/kg/h continuous intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: 5 IU/60kg intravenous infusion follow by 0.002 IU/kg/h continuous intravenous infusion
Study: NCT00016367

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Regimen A: Trastuzumab IV over 90 minutes on days 2 and 8.~Regimen B: Trastuzumab IV over 30-90 minutes on days 1, 8 and 15.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Regimen A: Trastuzumab IV over 90 minutes on days 2 and 8.~Regimen B: Trastuzumab IV over 30-90 minutes on days 1, 8 and 15.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Regimen A: Cisplatin IV over 2 hours on day 1 following gemcitabine.~Regimen B: Cisplatin IV over 2 hours on day 1.
Study: NCT04479306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Given PO
Study: NCT00016367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Regimen A: Cisplatin IV over 2 hours on day 1 following gemcitabine.~Regimen B: Cisplatin IV over 2 hours on day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Regimen A: Gemcitabine IV over 30 minutes on day 1. Gemcitabine IV over 30 minutes on day 8 following Trastuzumab.~Regimen B: Gemcitabine IV over 30 minutes on day 1. Gemcitabine IV over 30 minutes on day 8 following Trastuzumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Regimen A: Gemcitabine IV over 30 minutes on day 1. Gemcitabine IV over 30 minutes on day 8 following Trastuzumab.~Regimen B: Gemcitabine IV over 30 minutes on day 1. Gemcitabine IV over 30 minutes on day 8 following Trastuzumab.
Study: NCT00912080

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: genomic signature
Description: genomic signature analysis
Study: NCT02253823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EFV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EFV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPV/RTV - low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPV/RTV - high dose
Study: NCT01410656

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Implementation Intention
Description: Telephone implementation intention counseling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-completed implementation intention
Description: Self-administered implementation intention intervention
Study: NCT00659958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zonisamide
Description: 300 mg tablet. Maintenance dosing period of 12 weeks, at the beginning of which, physicians will decide to keep the 300 mg dose from the titration period, lower it to 200 mg, or take it up to 400 mg.
Study: NCT02418312

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: histamine-2 receptor antagonist
Description: famotidine 40 mg qd plus thienopyridine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo plus thienopyridine
Study: NCT02104271

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Argon Plasma Coagulation
Description: APC was performed during sigmoidoscopy exam. Bowel preparation begins on the eve of the exam associated with waste liquid diet without oral intake of 10mg of bisacodyl (5mg/dragee) at 14 o'clock and 18pm and 130ml of phosfoenema (16g of sodium phosphate monobasic monohydrate and 6g of sodium phosphate dibasic heptahydrate per 100ml) diluted in 100ml of orange juice or lemon to 19h. On the day of the exam is administered 130ml of phosfoenema rectally immediately before the exam.~All patients were previously sedated with fentanyl (0.05mg/ml), midazolam (5mg/5ml) and propofol (10mg/ml) and have intravenous introduction of the flexible colonoscope to the transverse colon to the exchange of gases following the routine of the Department of Endoscopy, Cancer Hospital Barretos.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Historical control
Description: APC was performed during sigmoidoscopy exam. Bowel preparation begins on the eve of the exam associated with waste liquid diet without oral intake of 10mg of bisacodyl (5mg/dragee) at 14 o'clock and 18pm and 130ml of phosfoenema (16g of sodium phosphate monobasic monohydrate and 6g of sodium phosphate dibasic heptahydrate per 100ml) diluted in 100ml of orange juice or lemon to 19h. On the day of the exam is administered 130ml of phosfoenema rectally immediately before the exam.~All patients were previously sedated with fentanyl (0.05mg/ml), midazolam (5mg/5ml) and propofol (10mg/ml) and have intravenous introduction of the flexible colonoscope to the transverse colon to the exchange of gases following the routine of the Department of Endoscopy, Cancer Hospital Barretos.
Study: NCT04019067

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MCE first
Description: Patients randomized to the MCE first group will have a MCE deployed as soon as possible once confirmed to fast for at least 8 hours.
Study: NCT01698918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus was self-administered as a daily dose of 10mg (two 5mg tablets) taken orally continuously until progression of disease, unacceptable toxicity or withdrawal of consent.
Study: NCT00622947

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: right temporal low frequency (1 hz) rTMS
Description: Right temporal low frequency (1 hz) rTMS.
Study: NCT01698918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 1st line study treatment: Letrozole was self administered as a daily dose of 2.5mg continuously until disease progression or any other reason for which the patient might be discontinued

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: 2nd Line Study Treatment: Exemestane was self administered as a daily dose of 25mg taken orally continuously until disease progression or any other reason for which the patient might be discontinued

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol-free dexamethasone mouth rinse (Stomatitis sub-study)
Description: Alcohol-free 0.5mg/5ml dexamethasone oral solution was self-administered at a daily dose of 10ml 3 times per day (participants with confirmed stomatitis who entered the stomatitis sub-study).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care to treat stomatitis (Stomatitis sub-study)
Description: Standard of care used to treat stomatitis at the patient's center (participants with confirmed stomatitis who entered the stomatitis sub-study).
Study: NCT04413526

Intervention type: PROCEDURE
Intervention: radiofrequency
Description: radiofrequency combined with liver resection

Intervention type: PROCEDURE
Intervention: TACE
Description: only TACE treatment

Intervention type: PROCEDURE
Intervention: TACE+radiofrequency
Description: TACE followed by radiofrequency
Study: NCT02791204

Intervention type: DEVICE
Intervention: SPECT/CT imaging following revascularization procedures
Description: Subjects will undergo resting perfusion imaging of the feet using two separate SPECT/CT systems. Subjects will be injected with a low dose radioisotope. Heated venous blood sampling will be obtained.
Study: NCT00622947

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham-rTMS
Description: The coil is angled 90 degrees away from the scalp
Study: NCT03483870

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate
Description: 200 ug morphine sulphate will be injected intrathecally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine Sulfate
Description: 200 ug morphine sulphate will be injected intrathecally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 mL of normal saline 0.9% IV injection
Study: NCT04479306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapanisertib
Description: Given PO